SANOVO Tests Early EGFR and MET Dual Blockade

Company HUTCHMED; AstraZeneca Event Type Phase 3 detailed data Modality Oral MET inhibitor plus EGFR inhibitor Asset Savolitinib plus osimertinib Target MET; EGFR Disease Area Untreated EGFR-mutant, MET-overexpressing advanced NSCLC Summary New Phase III data presented on 26 October show a large progression-free survival benefit…